reason report
outsiz sell-off revenu miss warrant pt
bottom line believ sell-off today
earn result overreact revenu miss
like reflect investor skeptic achiev compani
guidanc acknowledg narr enter
increas spend necessari would allow top-lin
expect realiz deviat narr
still believ fy guidanc still well within reach reiter
outperform rate lower price target
although appear cheap current stock level ebitda
vs peer group stock trade toward price target
acknowledg manag need demonstr
deliv guidanc avoid repeat larg top-lin miss
lower eu sale estim pt made minor chang
revenu forecast north america rest world row
lower estim eu sale onward
continu believ revenu grow north america
row consist compani guidanc howev
cautiou eu sale abil hit guidanc
expect flat year given weak perform
result total revenu forecast decreas
outer year also made minor chang
oper expens slightli lower expens throughout
year slight increas sg outer year non-
gaap ep forecast lower lower
ebitda declin
appli unchang ev/ebitda multipl yield new pt
vs prior
revenu miss mani factor blame key driver fx
disrupt serial total revenu
lower yoy consensu primarili driven weak
eu sale declin yoy consensu
unfavor foreign exchang fx impact cite major driver
revenu miss fx impact account
revenu miss adjust fx eu sale would
declin yoy miss consensu anoth unfavor
contributor temporari busi disrupt caus new
serial regul eu account miss
manag state serial issu resolv
third-parti manufactur compani come
normal state suppli
ev/ebitda multipl
net debt total capit
gener
year price history/av daili volume mil
compani inform svb leerink llc research
revenu
pleas refer page import disclosur price chart analyst certif
new product launch track reach guidanc new
product launch launch within year reach
sale launch expect
new product manag reiter previou guidanc
total sale new product launch clarifi would
come product launch sale happen
within year launch gx advair remain
new product launch impli gx advair
could achiev sale base analysi
prescript trend market share appear ambiti
goal analysi suggest annual sale see note
believ need aggress gain market
share without lose much price power current level order
achiev goal regard signific new launch
manag highlight biosimilar product fulphila neulasta
ogivri herceptin hulio humira europ yupelri ogivri
us
expect sg invest boost revenu initi
post above-consensu sg guidanc earn
sg expens came lower consensu
expect front-load follow-up convers
compani manag comment sg cadenc also due
time therefor could expect flow
outcom strateg review appear near
announc continu littl insight rang
option committe may assess manag comment
suggest announc outcom near term
although note similar commentari made
earn call februari
place outperform rate share base strong pipelin biosimilar
durabl ou busi growth off-set continu us base busi
gener eros support revenu growth potenti near-term
upsid consensu number limit competit copaxon advair though
difficult high visibl insulin/biosimilar growth driver
could expand multipl rel peer strong balanc sheet allow
share buy-back smaller bolt-on acquisit expand geograph and/or therapeut
use weight averag ev/ebitda multipl ebitda deriv
price target per share
gener advair opportun may smaller estim commerci uptak
biosimilar may take longer anticip growth ou market may slower
expect market penetr gener copaxon may improv biosimilar neulasta ramp
may slower estim remedi morgantown facil may take longer
allevi reach lower capac current estim
figur chang model
svb leerink estim note number except ep margin
figur chang model continu
svb leerink estim note number except ep margin
note number except ep margin
changevalu changevarianceconsensusactu vs consgeograph areanorth basic dilut non-gaap adjustmentstot one-tim net
brand
type event
event trial detail
date known
up/down
expect
outcom strateg review
svb leerink llc equiti research compani file
number except per share data
net debt ebitda ratio
number except per share data
number except per share data
assum ftf product
advair assum get approv
letairi approv end march
ulor settlement june tent approv
norvir/kaletra assum patent expir jan tent approv
tarceva undisclos settlement assum month last patent approv
sutent lost feb patent tent approv
jevtana assum patent expiri pend approv
brilinta assum jul patent expiri pend approv
brevibloc undisclos settlement assum month last patent expiri approv
januvia franchis assum compound patent tent approv
treanda assum launch end bendeka ode dec
vimpat lost patent expir pend approv
banzel settlement may approv
onglyza franchis lost jul patent pend approv
vyvans lost feb patent tent approv
assum ftf pipelin sub-tot
number except per share data
number except per share data
insulin collabor biocon
biosimilar collabor biocon momenta
ogivri biosim herceptin launch
number except per share data
number except per share data
number except per share data
number except per share data
prepaid expens current
current portion ltd
number except per share data
adjust reconcil ni net cash oper
litig settlement conting net
loss acquisition-rel foreign currenc deriv
loss equiti method invest
write financ fee
decreas increas work capit
paid acquisit net
purchas properti plant equip capital-expenditure
payment product right net
paid meda uncondit defer payment
settlement acquisition-rel foreign currenc deriv
proce sale asset subsidiari
purchas market secur
chang restrict cash
proce sale market securitin
net invest
payment financ fee
proce convert note hedg
proce issuance/ purchas ordinari share net
proce exercis stock option
tax paid relat net share settlement equiti award
acquisit non-controlling interest
net financ
effect cash chang exchang rate
net chang equival
